Avian Mycoplasma Vaccine: Principles, Efficacy, and Application in Poultry

Introduction

Avian mycoplasmosis represents a significant economic burden on the global poultry industry, primarily caused by Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) [1, 2]. These pathogens induce chronic respiratory disease, reproductive disorders, and synovitis, leading to reduced meat and egg production [3, 4]. Vaccination remains a cornerstone of control programs where elimination through biosecurity and depopulation is not feasible [4, 5]. This review examines the principles, efficacy, and practical application of [poultry mycoplasma vaccine] formulations, including live attenuated strains, inactivated bacterins, and novel recombinant vector technologies [1, 2, 6].

The development of effective [poultry mycoplasma vaccine] strategies requires a detailed understanding of host-pathogen interactions, immune evasion mechanisms, and the biophysical constraints of vaccine delivery [7, 8]. Mycoplasma species lack a cell wall and possess a highly plastic genome, which complicates the design of stable attenuated strains [5, 6]. Vaccination aims to reduce respiratory tract colonization, lesion formation, and vertical transmission while minimizing adverse reactions in vaccinated flocks [1, 7, 9].

Etiology and Epidemiology

MG is the primary etiological agent of chronic respiratory disease (CRD) in chickens and turkeys, often exacerbated by co-infections with respiratory viruses such as infectious bronchitis virus (IBV) or Escherichia coli [10, 11]. MS causes infectious synovitis and eggshell apex abnormalities (EAA) in layers [12, 13]. Mycoplasma meleagridis and Mycoplasma iowae affect turkeys, while Mycoplasma anserisalpingitidis is economically important in waterfowl [3]. Transmission occurs horizontally through aerosolized respiratory droplets and vertically via the egg, making hatchery-based control critical [9, 11].

Molecular typing methods, including pulsed-field gel electrophoresis (PFGE) and vlhA gene sequencing, differentiate field isolates from vaccine strains [13, 14]. Epidemiological surveillance relies on these tools to monitor vaccine persistence and detect emerging pathogenic variants [4].

Principles of Avian Mycoplasma Vaccines

Live Attenuated Vaccines

Live attenuated [poultry mycoplasma vaccine] strains are the most widely used category. Attenuation is achieved through chemical mutagenesis, serial passage, or targeted genetic modification, resulting in temperature-sensitive (ts+) or metabolically compromised phenotypes [3, 6, 15]. These vaccines colonize the upper respiratory tract, stimulating both mucosal (IgA) and systemic (IgG) immune responses [2, 8]. Key live vaccine strains include:

• F-strain (MG): A low-pathogenicity strain derived from a field isolate, used primarily in layers [1, 16, 17].
• ts-11 (MG): A temperature-sensitive mutant that replicates at the lower temperature of the upper respiratory tract (33-34°C) but is restricted at core body temperature (41°C) [8, 18, 19].
• 6/85 (MG): A non-temperature-sensitive attenuated strain, typically administered via fine spray aerosol [8, 18, 20].
• K-strain (MG): An attenuated strain used in broilers and layers, characterized by specific single nucleotide polymorphisms (SNPs) in the fruA gene [4, 21, 15].
• MS-H (MS): A temperature-sensitive mutant of MS strain 86079/7NS, harboring a frameshift mutation in the oppF1 gene, which truncates the OppF1 oligopeptide permease transporter [5, 22, 14, 23].

Inactivated Bacterins

Inactivated [poultry mycoplasma vaccine] formulations (bacterins) consist of whole mycoplasma cells killed by chemical treatment (e.g., formalin or beta-propiolactone) and emulsified in an adjuvant [1]. These vaccines induce humoral immunity but do not effectively stimulate mucosal IgA or cell-mediated responses [2]. They require multiple doses and are often used in combination with live vaccines to enhance protection [1].

Recombinant and Next-Generation Vaccines

Novel platforms include live recombinant Salmonella enterica serovar Typhimurium vectors expressing MG and MS antigens (GrpE and CrmA) [2]. These constructs elicit robust humoral (IgG), mucosal (IgA), and Th1-biased cellular responses (IFN-alpha, IL-1beta, TNF-alpha) while offering cross-protection against both MG and MS [2]. Other experimental approaches include metabolically attenuated MG mutants and temperature-sensitive M. anserisalpingitidis clones produced by N-methyl-N′-nitro-N-nitrosoguanidine (NTG) mutagenesis [3, 6].

Efficacy Assessment

Challenge Models and Outcome Parameters

Efficacy of [poultry mycoplasma vaccine] candidates is evaluated using controlled challenge models in specific-pathogen-free (SPF) chickens [1, 8]. Birds are vaccinated, then challenged via aerosol with a virulent strain (e.g., MG R-strain). Protection is assessed using several parameters:

• Tracheal colonization: Quantified by culture or PCR. Reduced colonization indicates immune blockade of adherence [1, 4].
• Tracheal lesion scores: Histopathological measurement of mucosal thickness and inflammatory infiltration, which are more discriminatory and reproducible than air sac lesion scoring [7].
• Air sac lesion scores: Gross pathological assessment of airsacculitis [1, 8].
• Ovarian regression: In layers, protection against reproductive tract pathology [1].
• Serological response: Measured by ELISA (e.g., pMGA-based for ts-11, MSPB-based for MS-H) [24, 25].

A recent comparative trial demonstrated that F-strain, alone or combined with a bacterin, significantly reduced tracheal colonization following R-strain challenge at 22 and 41 weeks of age [1]. However, only programmes including the live vaccine provided significant protection from respiratory lesions and ovarian regression [1]. In a second trial, the live plus bacterin combination significantly improved protection against challenge strain colonization and air sac lesions compared to live vaccine alone [1].

Differential Efficacy by Vaccine Strain

The ts-11 and 6/85 vaccines, administered via eye drop and fine aerosol respectively, induce comparable levels of protection against airsacculitis and tracheitis, despite differing kinetics of systemic antibody responses [8]. ts-11 elicits an initially strong antibody response that declines over time, while 6/85 shows a weaker initial response that increases gradually [8]. Both vaccines maintain protective efficacy against wild-type MG challenge up to 36 weeks post vaccination [8]. Poor systemic antibody responses after ts-11 vaccination in broiler breeders are not necessarily associated with susceptibility to challenge, indicating that cell-mediated immunity contributes to protection [26].

The K-strain vaccine has demonstrated efficacy in both broiler and layer chickens, reducing lesion scores and colonization [21, 15]. A mismatch amplification mutation assay (MAMA) has been developed to differentiate the K vaccine strain from field isolates by detecting a specific G88A substitution within the fruA gene [4].

The MS-H vaccine protects MS against challenge, reducing air sac lesions, synovitis, and eggshell apex abnormalities [12, 22, 23]. Complementation of the MS-H vaccine strain with wild-type oppF1 restored growth characteristics, confirming the role of this mutation in attenuation [5]. Non-temperature-sensitive revertants of MS-H have been isolated from field samples, underscoring the need for molecular monitoring [14].

Application in Poultry Flocks

Vaccination Routes and Dosage

Live [poultry mycoplasma vaccine] strains are administered via:

• Eye drop: Ensures precise dosing and robust mucosal immunity in individual birds. Recommended for ts-11 [8, 31].
• Fine spray/aerosol: Used for mass vaccination, particularly for 6/85 and K-strain in broilers [21, 8, 27].
• Drinking water: Less commonly used due to variability in water quality and consumption [27, 34, 35].

Reconstitution conditions significantly affect vaccine titer. Increasing sodium chloride concentration reduces MG vaccine survival in solution [34]. Water temperature during reconstitution also impacts titer, with optimal stability at lower temperatures [35].

Vaccination Programs

In layer flocks, F-strain or ts-11 is typically administered at 5-10 weeks of age, sometimes followed by a booster with an inactivated bacterin at 9-13 weeks [1, 17]. Broiler breeders may receive ts-11 at 6-10 weeks [31]. MS-H is administered to pullets at 4-8 weeks of age [22, 33].

The table below summarizes key vaccine strains and their characteristics.

Effects on Transmission and Production

Vaccination with live strains can reduce horizontal transmission of wild-type MG. F-strain vaccinated layers exhibited lower transmission rates to sentinel birds [9]. However, some live vaccine strains (e.g., ts-11, 6/85) can themselves be transmitted to unvaccinated contact birds, which may be desirable for flock coverage but raises concerns about reversion to virulence [18, 9].

Field evaluations of ts-11 and 6/85 in commercial layers over a 43-week laying cycle demonstrated no negative impact on egg production or egg quality parameters compared to unvaccinated challenged controls [20]. MS-H vaccination reduced the incidence of eggshell apex abnormalities in MS-infected flocks [12].

Safety and Reversion Risk

Safety of [poultry mycoplasma vaccine] strains is paramount. The MS-H vaccine has been shown to be safe in SPF and commercial birds, with no evidence of pathogenicity [28]. Temperature-sensitive clones of M. anserisalpingitidis (MA271) remained ts+ throughout an 8-week experiment, and re-isolates retained the temperature-sensitive phenotype [3]. Whole-genome sequencing of MA271 revealed 59 mutations relative to the parent strain, affecting genes involved in cellular processes and fitness [3].

In contrast, non-temperature-sensitive revertants of MS-H have been isolated from field samples, illustrating the need for molecular surveillance and the development of discriminatory diagnostic tools such as PFGE and vlhA sequencing [13, 14].

Diagnostic Differentiation and Control

Molecular Differentiation of Vaccine from Field Strains

Differentiating vaccine strains from field isolates is essential for monitoring vaccine take, persistence, and potential reversion [4]. The MAMA-K-fruA assay specifically recognizes a G88A SNP in the K-strain fruA gene, with sensitivity of 102-103 template copies per microliter [4]. Similarly, PFGE and DNA sequencing of the vlhA gene discriminate MS-H from field MS strains [13].

Improved serological assays, such as autologous recombinant MSPB ELISA for MS-H and pMGA ELISA for ts-11, provide enhanced specificity for detecting vaccine-induced antibodies [24, 25]. These assays are critical for distinguishing vaccinated flocks from naturally infected ones.

Biosecurity and Control Programs

Vaccination is most effective when integrated with comprehensive biosecurity measures. The decision to vaccinate depends on the prevalence of MG or MS in the region, the type of production (broiler, layer, breeder), and economic considerations [1, 21]. In multi-age farms, vaccination of replacement pullets is standard practice to maintain population immunity [17].

The Mermaid diagram below illustrates a decision framework for implementing a [poultry mycoplasma vaccine] program.

graph TD
    A[Evaluate flock MG/MS status], > B{Positive history?};
    B, Yes, > C[Select vaccine type];
    B, No, > D[Maintain biosecurity];
    C, > E{Layer or broiler?};
    E, Layer, > F[Live vaccine e.g. F-strain, ts-11];
    E, Broiler, > G[Live vaccine e.g. K-strain, 6/85];
    F, > H[Optional bacterin booster at 9-13 wks];
    G, > I[Mass administration via spray/drinking water];
    H, > J[Monitor seroconversion and shedding];
    I, > J;
    J, > K{If shedding detected?};
    K, Yes, > L[Perform MAMA/PFGE to differentiate strain];
    K, No, > M[Continue routine monitoring];
    L, > N{Is it vaccine strain?};
    N, Yes, > O[Acceptable persistence];
    N, No, > P[Investigate field infection and treat];
    O, > M;
    P, > Q[Revise vaccination protocol];

Conclusion

The development of [poultry mycoplasma vaccine] has provided poultry producers with effective tools to mitigate the production losses caused by MG and MS. Live attenuated vaccines, including F-strain, ts-11, 6/85, K-strain, and MS-H, offer robust protection when administered via appropriate routes and schedules. Inactivated bacterins serve as useful adjuncts, particularly for boosting systemic immunity in long-lived layers. Next-generation recombinant vaccines delivered via bacterial vectors represent a promising frontier for inducing broad mucosal and cellular immunity [2]. Continued molecular surveillance using discriminatory assays (MAMA, PFGE, vlhA sequencing) is essential to monitor vaccine persistence and detect emergence of pathogenic reventants or field strains [4, 13, 14]. Standardization of efficacy assessment models, particularly the use of tracheal lesion measurements, will facilitate direct comparisons between vaccine studies and improve evidence-based selection of vaccination strategies [7].

References

[1] Ferguson-Noel, N., Dos Santos, M. D., Ehsan, M., et al. Comparison of the efficacy of Mycoplasma gallisepticum vaccine programmes in chickens. Avian Pathology. Link

[2] Sabir, R., Liu, M., Saeed, H. A., et al. Next-generation live vector vaccine targeting Mycoplasma synoviae and Mycoplasma gallisepticum via recombinant Salmonella. Vaccine. Link

[3] Bekő, K., Grózner, D., Mitter, A., et al. Development and evaluation of temperature-sensitive Mycoplasma anserisalpingitidis clones as vaccine candidates. Avian Pathology. Link

[4] Bekő, K., Kovács, Á. B., Kreizinger, Z., et al. Development of mismatch amplification mutation assay for the rapid differentiation of Mycoplasma gallisepticum K vaccine strain from field isolates. Avian Pathology. Link

[5] Kordafshari, S., Marenda, M., Agnew, R., et al. Complementation of the Mycoplasma synoviae MS-H vaccine strain with wild-type oppF1 influences its growth characteristics. Avian Pathology. Link

[6] Gates, A., Frasca, S., Nyaoke, A., et al. Comparative assessment of a metabolically attenuated Mycoplasma gallisepticum mutant as a live vaccine for the prevention of avian respiratory mycoplasmosis. Vaccine. Link

[7] Kulappu Arachchige, S. N., Underwood, G., Andrews, D. M., et al. Measures of tracheal lesions are more discriminatory and reproducible indications of chronic respiratory disease caused by Mycoplasma gallisepticum in poultry. Avian Pathology. Link

[8] Noormohammadi, A., Whithear, K. Comparison of the short-term and long-term efficacies of the Mycoplasma gallisepticum vaccines ts-11 and 6/85. Avian Pathology. Link

[9] Feberwee, A., Landman, W. J. M., von Banniseht-Wysmuller, T., et al. The effect of a live vaccine on the horizontal transmission of Mycoplasma gallisepticum. Avian Pathology. Link

[10] Bwala, D. G., Solomon, P., Duncan, N., et al. Assessment of Mycoplasma gallisepticum vaccine efficacy in a co-infection challenge model with QX-like infectious bronchitis virus. Avian Pathology. Link

[11] Hopkins, S., Yoder, H. Increased incidence of airsacculitis in broilers infected with

[12] Feberwee, A., Morrow, C. J., Ghorashi, S. A., et al. Effect of a live Mycoplasma synoviae vaccine on the production of eggshell apex abnormalities induced by a M. synoviae infection preceded by an infection with infectious bronchitis virus D1466. Avian Pathology. Link

[13] Harada, K., Kijima-Tanaka, M., Uchiyama, M., et al. Molecular Typing of Japanese Field Isolates and Live Commercial Vaccine Strain of Mycoplasma synoviae Using Improved Pulsed-Field Gel Electrophoresis and vlhA Gene Sequencing. Avian Diseases. Link

[14] Noormohammadi, A., Jones, J. F., Harrigan, K., et al. Evaluation of the Non-Temperature-Sensitive Field Clonal Isolates of the Mycoplasma synoviae Vaccine Strain MS-H. Avian Diseases. Link

[15] Ferguson-Noel, N., Laibinis, V., Kleven, S. Evaluation of Mycoplasma gallisepticum K-Strain as a Live Vaccine in Chickens. Avian Diseases. Link

[16] Purswell, J., Evans, J. D., Branton, S. Serologic Response of Roosters to Gradient Dosage Levels of a Commercially Available Live F Strain-Derived Mycoplasma gallisepticum Vaccine Over Time. Avian Diseases. Link

[17] Branton, S., Leigh, S., Purswell, J., et al. A Chronicle of Serologic Response in Commercial Layer Chickens to Vaccination with Commercial F Strain Mycoplasma gallisepticum Vaccine. Avian Diseases. Link

[18] Ley, D. H., McLaren, J. M., Miles, A. M., et al. Transmissibility of live Mycoplasma gallisepticum vaccine strains ts-11 and 6/85 from vaccinated layer pullets to sentinel poultry. Avian Diseases. Link

[19] Bíró, J., Povazsán, J., Kőrösi, L., et al. Safety and efficacy of Mycoplasma gallisepticum TS-11 vaccine for the protection of layer pullets against challenge with virulent M. gallisepticum R-strain. Avian Pathology. Link

[20] Branton, S., Bearson, S., Bearson, B., et al. The Effects of 6/85 Live Mycoplasma gallisepticum Vaccine in Commercial Layer Hens over a 43-Week Laying Cycle on Egg Production, Selected Egg Quality Parameters, and Egg Size Distribution When Challenged Before Beginning of Lay. Avian Diseases. Link

[21] Ferguson-Noel, N., Williams, S. M. The efficacy of Mycoplasma gallisepticum K-strain live vaccine in broiler and layer chickens. Avian Pathology. Link

[22] Markham, J. E., Scott, P. C., Whithear, K. Field evaluation of the safety and efficacy of a temperature-sensitive Mycoplasma synoviae live vaccine. Avian Diseases. Link

[23] Markham, J. F., Morrow, C., Whithear, K. Efficacy of a temperature-sensitive Mycoplasma synoviae live vaccine. Avian Diseases. Link

[24] Noormohammadi, A., Browning, G., Jones, J. F., et al. Improved detection of antibodies to Mycoplasma synoviae vaccine MS-H using an autologous recombinant MSPB enzyme-linked immunosorbent assay. Avian Pathology. Link

[25] Noormohammadi, A., Browning, G., Cowling, P., et al. Detection of Antibodies to Mycoplasma gallisepticum Vaccine ts-11 by an Autologous pMGA Enzyme-Linked Immunosorbent Assay. Avian Diseases. Link

[26] Noormohammadi, A., Jones, J., Underwood, G., et al. Poor Systemic Antibody Response After Vaccination of Commercial Broiler Breeders with Mycoplasma gallisepticum Vaccine ts-11 Not Associated with Susceptibility to Challenge. Avian Diseases. Link

[27] Evans, J. D., Branton, S., Leigh, S. Effect of Dosage and Vaccination Route on Transmission of a Live Attenuated Mycoplasma gallisepticum Vaccine: A Broiler Model. Avian Diseases. Link

[28] Markham, J. F., Morrow, C., Scott, P., et al. Safety of a temperature-sensitive clone of Mycoplasma synoviae as a live vaccine. Avian Diseases. Link

[29] Rodríguez, R., Kleven, S. Evaluation of a vaccine against Mycoplasma gallisepticum in commercial broilers. Avian Diseases. Link

[30] Ferguson, N., Leiting, V., Kleven, S. Safety and Efficacy of the Avirulent Mycoplasma gallisepticum Strain K5054 as a Live Vaccine in Poultry. Avian Diseases. Link